- Adding whole-brain radiotherapy (WBRT) to anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) significantly prolongs survival in patients with EGFR+ NSCLC brain metastases.
Why this matters
- As treatments advance and survival improves, emerging concerns for neurocognitive toxicity have stoked debate regarding the role of WBRT in treating NSCLC brain metastases.
- Study of 141 patients with EGFR+ NSCLC-related brain metastases receiving EGFR-TKIs; 94 (66.7%) also underwent WBRT.
- Median follow-up was 20.3 months.
- Funding: Kaohsiung Medical University Hospital; Ministry of Science and Technology, Taiwan.
- 1-year OS rate was greater with TKI+WBRT (81.9%) vs TKI alone (81.9% vs 59.6%; P=.002).
- Median OS after brain metastasis diagnosis:
- 14.3 (95% CI, 9.5-18.3) months for TKI+WBRT, and
- 2.3 (95% CI, 2-2.6) months for TKI alone.
- Retrospective, monocentric design.
- OS endpoint may not correlate with tumor response.